Profile data is unavailable for this security.
About the company
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity, and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule, FXR314.
- Revenue in USD (TTM)49.00bn
- Net income in USD11.11bn
- Incorporated1901
- Employees47.00k
- LocationEli Lilly and CoLilly Corporate Ctr, Drop Code 1094INDIANAPOLIS 46285United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Verve Therapeutics Inc | -4.44% | 1.25bn |
| SiteOne Therapeutics Inc | 8.13% | 1.00bn |
| Scorpion Therapeutics Inc | -3.52% | 2.50bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | 34.13bn | 5.93bn | 160.37bn | 28.00k | 27.22 | 25.84 | 13.90 | 4.70 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Merck & Co Inc | 63.92bn | 17.43bn | 204.70bn | 75.00k | 11.87 | 4.24 | 9.26 | 3.20 | 6.87 | 6.87 | 25.19 | 19.21 | 0.5786 | 2.31 | 5.77 | 852,293.30 | 15.79 | 9.52 | 20.46 | 12.64 | 77.07 | 73.47 | 27.30 | 17.87 | 1.16 | 23.90 | 0.4186 | 72.96 | 6.74 | 10.40 | 4,589.59 | 24.64 | -0.5885 | 6.66 |
| AbbVie Inc | 57.37bn | 4.16bn | 338.09bn | 55.00k | 81.61 | 238.08 | 26.81 | 5.89 | 2.35 | 2.35 | 32.39 | 0.804 | 0.4025 | 3.83 | 4.70 | 1,043,036.00 | 2.95 | 5.44 | 4.06 | 7.09 | 70.69 | 68.89 | 7.33 | 13.73 | 0.6359 | 7.80 | 0.9795 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 7.69 |
| Johnson & Johnson | 90.63bn | 22.66bn | 392.14bn | 138.10k | 17.43 | -- | 17.32 | 4.33 | 9.35 | 9.35 | 37.37 | -- | -- | -- | -- | 656,241.90 | -- | 8.63 | -- | 11.73 | 67.98 | 68.70 | 25.00 | 18.29 | -- | -- | -- | 74.74 | 4.30 | 1.60 | 5.55 | -1.43 | 4.81 | 5.54 |
| Eli Lilly And Co | 49.00bn | 11.11bn | 721.70bn | 47.00k | 61.91 | 45.78 | 55.79 | 14.73 | 12.30 | 12.30 | 54.25 | 16.63 | 0.6392 | 1.16 | 4.92 | 1,042,621.00 | 14.49 | 12.63 | 21.26 | 19.32 | 81.70 | 78.25 | 22.66 | 21.08 | 1.06 | 22.43 | 0.7085 | 55.34 | 32.00 | 15.08 | 102.08 | 17.95 | 44.08 | 15.05 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 75.46m | 7.96% |
| PNC Bank, NA (Investment Management)as of 31 Mar 2025 | 51.07m | 5.39% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 41.47m | 4.38% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 34.44m | 3.63% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 24.54m | 2.59% |
| Geode Capital Management LLCas of 31 Mar 2025 | 18.53m | 1.96% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 18.38m | 1.94% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 17.98m | 1.90% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 15.75m | 1.66% |
| PRIMECAP Management Co.as of 31 Mar 2025 | 14.78m | 1.56% |
